{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009526","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.874499+00:00","generated_at":"2026-05-15T15:40:42.018530+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake","bullets":["Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).","Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.","Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.","Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.","Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009526","json":"https://secwatch.observer/filing/0001493152-26-009526.json","markdown":"https://secwatch.observer/filing/0001493152-26-009526.md","text":"https://secwatch.observer/filing/0001493152-26-009526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/0001493152-26-009526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:40:42.018530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bc62097b7aa7e9793d86bcc42aa84c5522c8e70","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amended and Restated Share Exchange Agreement with Orbit Capital Inc. valued at Amends and restates the Share Exchange Agreement dated November 21, 2025 (effective 2025-11-21).","evidence_excerpt":"On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary of the Company (“Liora”) and Orbit Capital Inc., (“Orbit”), entered into an Amended and Restated Share Exchange Agreement with an effective date of November 21, 2025 (the A&R Agreement).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/0001493152-26-009526-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Orbit Capital Inc."},{"label":"Value","value":"Amends and restates the Share Exchange Agreement dated November 21, 2025"},{"label":"Effective","value":"2025-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}